2022
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review Of Immunology 2022, 40: 45-74. PMID: 35471840, DOI: 10.1146/annurev-immunol-070621-030155.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsB7-H1 AntigenHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 ReceptorT-LymphocytesTumor MicroenvironmentConceptsAnti-PD therapyCancer immunotherapyMechanisms of resistanceImmune inhibitory moleculesFraction of patientsResistance mechanismsNormalization cancer immunotherapyAdditional immunotherapyPD-1Clinical evidenceAntigen presentationT cellsSolid tumorsTherapy resistanceH1 pathwayTumor microenvironmentImmunotherapyInhibitory moleculesHematopoietic malignanciesCancer treatmentTherapyPatientsCurrent studyCancer dataMalignancy
2018
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175: 313-326. PMID: 30290139, PMCID: PMC6538253, DOI: 10.1016/j.cell.2018.09.035.Peer-Reviewed Original ResearchMeSH KeywordsB7-H1 AntigenCombined Modality TherapyCTLA-4 AntigenHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 ReceptorTumor MicroenvironmentConceptsImmune-related adverse eventsCancer immunotherapyImmune normalizationFrequent immune-related adverse eventsB7-H1/PDHigher objective response rateFuture cancer immunotherapyObjective response rateRare objective responsesAntitumor immune responseImmune activation mechanismsObjective responseAdverse eventsImmune enhancementTumor responseImmune deficiencyCancer indicationsDifferent therapiesImmune responseToxicity profileImmunotherapyResponse rateFDA approvalTumor microenvironmentDistinct mechanisms